NewAmsterdam Pharma Co NV
NAMS
Company Profile
Business description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Contact
Gooimeer 2-35
NaardenNH1411 DC
NLDT: +31 352062971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
77
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,637.50 | 22.80 | -0.26% |
| CAC 40 | 7,737.20 | 14.69 | -0.19% |
| DAX 40 | 23,930.67 | 66.81 | -0.28% |
| Dow JONES (US) | 42,291.71 | 21.64 | 0.05% |
| FTSE 100 | 8,774.26 | 1.88 | 0.02% |
| HKSE | 23,157.97 | 131.80 | -0.57% |
| NASDAQ | 19,248.30 | 134.54 | 0.70% |
| Nikkei 225 | 37,470.67 | 494.43 | -1.30% |
| NZX 50 Index | 12,418.89 | 137.58 | 1.12% |
| S&P 500 | 5,935.57 | 23.88 | 0.40% |
| S&P/ASX 200 | 8,414.10 | 20.60 | -0.24% |
| SSE Composite Index | 3,347.49 | 15.96 | -0.47% |